{
  "source": "PA-Med-Nec-Lokelma.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2100-10\nProgram Prior Authorization/Medical Necessity\nMedication Lokelma® (sodium zirconium cyclosilicate), Veltassa® (patiromer)\nP&T Approval Date 6/2016, 6/2017, 8/2018, 12/2018, 3/2020, 6/2021, 6/2022, 6/2023 6/2024,\n7/2024\nEffective Date 10/1/2024\n1. Background:\nLokelma and Veltassa are indicated for the treatment of hyperkalemia. Lokelma and\nVeltassa should not be used as an emergency treatment for life threatening hyperkalemia\nbecause of its delayed onset of action. Non-emergent hyperkalemia is generally treated by\naddressing the reversible causes, such as removing drugs that may be causing impaired\nrenal function, removing or adjusting medications that directly cause hyperkalemia, and\ninitiating therapies for potassium removal.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Lokelma and Veltassa will be approved based on all of the following criteria:\na. Diagnosis of non-life threatening hyperkalemia\nb. Where clinically appropriate, loop or thiazide diuretic therapy for potassium\nremoval has failed\nc. Patient follows a low potassium diet (less than or equal to 3 grams per day)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Lokelma or Veltassa will be approved based on both of the following criteria:\na. Patient has a positive clinical response to Lokelma or Veltassa therapy and\ncontinues to require treatment for hyperkalemia\nb. Patient follows a low potassium diet (less than or equal to 3 grams per day)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, dia",
    "are Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class\n• Supply limits may be in place\n4. References:\n1. Veltassa [package insert]. Redwood City, CA; Vifor Pharma, Inc.: October 2023.\n2. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and\nhyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372:211.\n3. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone\nsystem. N Engl J Med 2004; 351:585.\n4. Khanna A, White WB. The management of hyperkalemia in patients with cardiovascular\ndisease. Am J Med. 2009 Mar. 122(3):215-21\n5. Lokelma [package insert]. Wilmington, DE; AstraZeneca: February 2024.\n6. Mount D. Treatment and prevention of hyperkalemia in adults. Sterns, R (Ed). UpToDate.\nWaltham, MA: UpToDate Inc. February 2024. Accessed May, 1 2024.\n7. De Nicola L, Ferraro PM, Montagnani A, Pontremoli R, Dentali F, Sesti G.\nRecommendations for the management of hyperkalemia in patients receiving renin-\nangiotensin-aldosterone system inhibitors. Intern Emerg Med. 2024 Mar;19(2):295-306. doi:\n10.1007/s11739-023-03427-0. Epub 2023 Sep 29. PMID: 37775712; PMCID:\nPMC10954964.\n8. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic\nKidney Disease. Kidney Int. 2024;105(4S): S117–S314. Kidney Disease: Improving Global\nOutcomes (KDIGO) Diabetes Work Group.\nProgram Prior Authorization/Medical Necessity – Veltassa, Lokelma\nChange Control\nDate Change\n6/2016 New program\n6/2017 Annual review. Updated reference.\n8/2018 Annual review. Updated references.\n12/2018 Added Lokelma. Updated references.\n3/2020 Updated references.\n6/2021 Updated references.\n6/2022 Updated references.\n6/2023 Annual review. Updated re",
    ".\n8/2018 Annual review. Updated references.\n12/2018 Added Lokelma. Updated references.\n3/2020 Updated references.\n6/2021 Updated references.\n6/2022 Updated references.\n6/2023 Annual review. Updated references.\n6/2024 Annual review. Updated references.\n7/2024 Removed requirement to adjust medications.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}